A groundbreaking clinical study, spearheaded by Stanford Medicine and an international consortium of researchers, has unveiled a revolutionary prosthetic eye system that has partially restored vision in individuals suffering from advanced age-related macular degeneration (AMD), a leading cause of irreversible blindness. The innovative technology, combining a minuscule wireless chip implanted at the back of the eye with a pair of sophisticated smart glasses, has empowered a significant majority of participants to regain the ability to read within a year of receiving the implant. In a testament to its efficacy, 27 out of 32 participants in the trial achieved visual sharpness comparable to 20/42 vision, augmented by the digital capabilities of the advanced eyewear, including adjustable zoom and enhanced contrast. These pivotal findings, representing a monumental leap in the restoration of functional vision, were formally published on October 20th in the prestigious New England Journal of Medicine.

The implant, christened PRIMA, is the culmination of decades of dedicated scientific endeavor and represents the first prosthetic eye device capable of restoring usable vision to individuals who have previously faced untreatable vision loss. This pioneering technology enables patients to discern shapes and patterns, a critical level of vision known as "form vision." Dr. Daniel Palanker, a distinguished professor of ophthalmology and co-senior author of the study, emphasized the profound significance of this achievement: "All previous attempts to provide vision with prosthetic devices resulted in basically light sensitivity, not really form vision. We are the first to provide form vision." The collaborative research effort was co-led by Dr. José-Alain Sahel, a professor of ophthalmology at the University of Pittsburgh School of Medicine, with Dr. Frank Holz of the University of Bonn in Germany serving as the lead author, underscoring the global nature of this breakthrough.

The PRIMA system operates through a synergistic interaction between two key components: a miniature camera integrated into a pair of specialized glasses and a wireless microchip surgically implanted within the retina. The camera captures visual information from the external environment and transmits it as infrared light to the retinal implant. This implant then ingeniously converts the infrared signals into electrical impulses. These electrical signals effectively mimic the function of the damaged photoreceptor cells, which are naturally responsible for detecting light and relaying visual data to the brain. The development of the PRIMA project is the result of a lengthy and intricate scientific journey, involving numerous iterative prototypes, extensive animal testing, and a crucial initial human trial, solidifying its scientific rigor and potential.

Dr. Palanker’s visionary concept for this technology originated two decades ago, during his research with ophthalmic lasers for treating various eye disorders. He shared his pivotal realization: "I realized we should use the fact that the eye is transparent and deliver information by light." The ambitious vision conceived in 2005 has now materialized into a device that is demonstrably effective in patients, exceeding initial expectations.

The clinical trial specifically focused on participants who had reached an advanced stage of age-related macular degeneration characterized by geographic atrophy. This debilitating condition progressively erodes central vision and affects an estimated over 5 million individuals worldwide, standing as the primary cause of irreversible blindness in older adults. In macular degeneration, the light-sensitive photoreceptor cells, crucial for detailed central vision, deteriorate, leaving patients with only limited peripheral vision. However, a critical aspect of this condition is that many of the retinal neurons responsible for processing visual information often remain intact. The PRIMA system ingeniously capitalizes on these surviving neural pathways.

The implant itself is remarkably small, measuring a mere 2 by 2 millimeters, and is precisely positioned in the area of the retina where the photoreceptors have been lost. Unlike natural photoreceptors that respond to visible light, the PRIMA chip is designed to detect infrared light emitted by the accompanying smart glasses. Dr. Palanker explained the strategic choice of infrared light: "The projection is done by infrared because we want to make sure it’s invisible to the remaining photoreceptors outside the implant."

This innovative design facilitates a unique synergistic integration of the patient’s remaining natural peripheral vision with the newly restored prosthetic central vision. This simultaneous perception allows for enhanced spatial orientation and improved mobility. "The fact that they see simultaneously prosthetic and peripheral vision is important because they can merge and use vision to its fullest," Dr. Palanker noted, highlighting the integrated visual experience. Furthermore, the PRIMA implant is photovoltaic, meaning it generates its own electrical current solely from light. This self-sustaining power source enables it to operate wirelessly and be safely implanted beneath the retina, eliminating the need for external power sources and cumbersome cables that were characteristic of earlier artificial eye devices.

The recent trial recruited 38 patients, all over the age of 60, who had been diagnosed with geographic atrophy due to AMD and exhibited visual acuity worse than 20/320 in at least one eye. Following a surgical implantation of the chip in one eye, patients were fitted with the smart glasses four to five weeks later. While some participants could perceive patterns immediately after activation, all patients demonstrated a progressive improvement in their visual acuity over several months of dedicated training. Dr. Palanker drew a parallel to the rehabilitation process for cochlear implants, stating, "It may take several months of training to reach top performance — which is similar to what cochlear implants require to master prosthetic hearing."

Of the 32 participants who successfully completed the one-year trial, a remarkable 27 were able to read, and 26 showed clinically meaningful improvements in their visual acuity, defined as the ability to discern at least two additional lines on a standard eye chart. On average, participants experienced an improvement of five lines on the eye chart, with one individual achieving an extraordinary twelve-line improvement. In their daily lives, participants utilized the prosthesis to engage in activities such as reading books, deciphering food labels, and identifying subway signs. The smart glasses provided crucial functionalities, allowing users to adjust contrast and brightness, and magnify their field of vision up to twelve times. The user satisfaction was notably high, with two-thirds of the participants reporting medium to high levels of satisfaction with the device. While nineteen participants experienced side effects, including ocular hypertension, peripheral retinal tears, and subretinal hemorrhage, none were life-threatening, and almost all resolved within a two-month period, underscoring the generally favorable safety profile of the implant.

Looking towards the future, the PRIMA device, in its current iteration, provides black-and-white vision without nuanced grayscale. However, Dr. Palanker is actively developing software to introduce a full spectrum of grayscale vision. He elaborated on the patients’ priorities: "Number one on the patients’ wish list is reading, but number two, very close behind, is face recognition. And face recognition requires grayscale." Beyond grayscale, Dr. Palanker is also engineering chips designed to offer significantly higher resolution vision. The current resolution is limited by the size of the pixels on the chip, which are 100 microns wide, resulting in 378 pixels per chip. A next-generation version, already tested successfully in rats, aims to incorporate pixels as small as 20 microns, thereby accommodating approximately 10,000 pixels per chip. This advancement holds the potential to provide a patient with 20/80 vision, which, with electronic zoom, could approach 20/20 clarity. Dr. Palanker also intends to explore the efficacy of the PRIMA device for other forms of blindness caused by photoreceptor loss. He concluded with optimism, "This is the first version of the chip, and resolution is relatively low. The next generation of the chip, with smaller pixels, will have better resolution and be paired with sleeker-looking glasses."

The groundbreaking research involved a vast network of collaborators from esteemed institutions worldwide, including the University of Bonn (Germany), Hôpital Fondation A. de Rothschild (France), Moorfields Eye Hospital and University College London, Ludwigshafen Academic Teaching Hospital, University of Rome Tor Vergata, Medical Center Schleswig-Holstein, University of Lübeck, L’Hôpital Universitaire de la Croix-Rousse and Université Claude Bernard Lyon 1, Azienda Ospedaliera San Giovanni Addolorata, Centre Monticelli Paradis and L’Université d’Aix-Marseille, Intercommunal Hospital of Créteil and Henri Mondor Hospital, Knappschaft Hospital Saar, Nantes University, University Eye Hospital Tübingen, University of Münster Medical Center, Bordeaux University Hospital, Hôpital National des 15-20, Erasmus University Medical Center, University of Ulm, Science Corp., University of California, San Francisco, University of Washington, University of Pittsburgh School of Medicine, and Sorbonne Université. The study received crucial funding from Science Corp., the National Institute for Health and Care Research, Moorfields Eye Hospital National Health Service Foundation Trust, and University College London Institute of Ophthalmology, underscoring the collaborative and well-supported nature of this transformative research.